With the 2020 election just over a year away, House Speaker Nancy Pelosi (D-CA) has unveiled the Democratic Party’s answer to public discontent over high prescription drug prices.
It’s time to catch up on recent news in Wisconsin’s innovation community. Read on for details.
The treatment landscape for lung cancer has shifted significantly over the past few years, and more changes could be on the way. At the World Conference on Lung Cancer in Barcelona this weekend a number of drug makers trotted out... Read more »
[Updated 8/26/19, 10:30am. See below.] Remember when the new wave of expensive cholesterol-lowering drugs—known as PCSK9 inhibitors—was supposed to give the healthcare system a financial heart attack?
Far from it. Four years after approval the two PCSK9 blockers... Read more »
The increasing popularity of Amazon’s annual Prime Day, Cyber Monday, and other online shopping-themed occasions is one of many indicators more Americans are relying on mobile devices and computers, not malls, to shop.
It’s no secret the so-called “Amazon effect,” a... Read more »
Ford subsidiary Autonomic today announced a step forward in its drive to expand the online mobility hub it built to manage digital interactions among cars, drivers, fleets, service providers, and auto manufacturers—including Ford’s rivals.
We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7 billion in 2018, and Novartis reportedly... Read more »
It’s time to catch up on some recent headlines from Wisconsin’s innovation clusters:
Gene therapy has become one of the hottest fields in biomedicine, with two treatments approved in the US already and several more on the way. But surprise news this week regarding Zolgensma, the recently approved spinal muscular atrophy treatment, cast... Read more »
Many companies developing artificial intelligence software for healthcare are trying to improve doctors’ ability to diagnose disease. Fewer emerging healthcare AI businesses are focused on what happens after a diagnosis, aiming to figure out how treatments are working.
One of them,... Read more »
Three years ago, the FDA made one of the most polarizing decisions in its history. It approved a drug for the rare genetic disease Duchenne muscular dystrophy on the slimmest of evidence, a watershed moment that caused a highly publicized rift... Read more »
What will the legacy be of Jeff Leiden, the longtime CEO of Vertex Pharmaceuticals?
Vertex surprised Wall Street this week by announcing Leiden’s seven-year run will end next spring. In some ways, his legacy is already written. He steered Vertex... Read more »
Founder of Swallow Solutions
Software Engineer at Skelmir
Baird Capital operating partner
CEO of Dynamis Corporation
Gravy Live co-founder
Founder and CEO of Propagate Health
Executive director of the Milwaukee Institute
Co-founder and CEO of Elucent Medical
Founder & CEO of Forward Health Group
Director, Genome Center, University of Wisconsin-Madison; Principal Investigator, Lloyd Smith Research Group, University of Wisconsin-Madison; Chemistry Professor, University of Wisconsin-Madison